Aer Therapeutics

Website

Aer Therapeutics, Inc.

15 Investors
Biopharmaceuticals
RALEIGH, NC

Aer Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of innovative therapies targeting mucus-related issues in lung diseases. The company's primary focus is on creating inhalable treatments to address airway mucus plugs, which are common in conditions like COPD and asthma.

Products & Team

AER-01

Inhaled Mucolytic TherapySeed

AER-01 is a lead therapeutic candidate designed to dissolve mucus plugs in the airways of patients with severe respiratory diseases. Developed through extensive academic collaborations, it is an inhaled thiol-saccharide mucolytic agent intended to improve lung function and ease breathing difficulties.

Value Proposition

AER-01 aims to alleviate breathing difficulties by effectively breaking down mucus plugs, thereby improving respiratory function in patients suffering from various lung diseases.

Pain Points

These patients commonly experience significant challenges due to airway obstruction from mucus plugs, leading to breathing difficulties and decreased quality of life.

Inhaled delivery systemTargets airway mucus plugsInvolves cutting-edge thiol-saccharide technology
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
RALEIGH, NC
Primary headquarters

Funding History

Total Raised:
$5.0M
E

Equity Offering

Closed
January 2025
$5.0M
Raised
Use of Proceeds
Proceeds will be used for working capital, which may include normal compensation to executive officers.
Progress
100%
Raised
$5.0M
Target
$5.0M
#000199860925000004